We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+0.23%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.56B
AUM Growth
-$299M
Cap. Flow
+$625M
Cap. Flow %
8.26%
Top 10 Hldgs %
53.85%
Holding
87
New
11
Increased
24
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
RXRX icon
Recursion Pharmaceuticals
RXRX
+$134M
2
CLYM
Climb Bio
CLYM
+$122M
3
ACLX
Arcellx
ACLX
+$87.2M
4
EVH icon
Evolent Health
EVH
+$71M
5
RNAM
Avidity Biosciences
RNAM
+$60.8M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$91.9M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$54.6M
3
CTKB icon
Cytek Biosciences
CTKB
+$45.7M
4
VXRT
Vaxart
VXRT
+$20M
5
EYPT icon
EyePoint Inc
EYPT
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
26
Axsome Therapeutics
AXSM
$12.1B
$80.5M 1.06%
1,000,000
– –
APGE icon
27
Apogee Therapeutics
APGE
$10.2B
$77.2M 1.02%
1,961,863
-16,038
-0.8% -$778K
GHRS icon
28
GH Research
GHRS
$1.95B
$77M 1.02%
6,601,689
+349,975
+6% +$4.2M
GPCR icon
29
Structure Therapeutics
GPCR
$3.52B
$74.5M 0.99%
1,896,772
+386,410
+26% +$15.9M
LENZ
30
LENZ Therapeutics
LENZ
$181M
$72.3M 0.96%
4,178,823
– –
FULC icon
31
Fulcrum Therapeutics
FULC
$248M
$72M 0.95%
11,609,704
– –
NKTX icon
32
Nkarta
NKTX
$154M
$63.9M 0.84%
10,805,129
– –
DNTH icon
33
Dianthus Therapeutics
DNTH
$6.16B
$60.4M 0.8%
2,333,000
– –
MLYS icon
34
Mineralys Therapeutics
MLYS
$2.31B
$56.8M 0.75%
4,850,984
– –
ITOS
35
DELISTED
iTeos Therapeutics
ITOS
$52.2M 0.69%
3,517,259
-900,000
-20% -$12.9M
URGN icon
36
UroGen Pharma
URGN
$2B
$51.7M 0.68%
3,083,430
– –
PRAX icon
37
Praxis Precision Medicines
PRAX
$8.58B
$51.1M 0.68%
1,235,599
+407,219
+49% +$19.2M
ELVN icon
38
Enliven Therapeutics
ELVN
$3.85B
$49.6M 0.66%
2,122,465
– –
ACRV icon
39
Acrivon Therapeutics
ACRV
$65.1M
$48.4M 0.64%
8,340,508
+3,530,000
+73% +$28.4M
ATXS
40
DELISTED
Astria Therapeutics
ATXS
$45.9M 0.61%
5,043,756
+630,606
+14% +$6.16M
BCYC
41
Bicycle Therapeutics
BCYC
$280M
$45.6M 0.6%
2,253,000
+1,453,000
+182% +$32.8M
CGON icon
42
CG Oncology
CGON
$6.44B
$44.1M 0.58%
1,397,433
– –
LRMR icon
43
Larimar Therapeutics
LRMR
$398M
$43.8M 0.58%
6,045,351
– –
ABOS icon
44
Acumen Pharmaceuticals
ABOS
$157M
$36.1M 0.48%
14,932,063
– –
TRML
45
DELISTED
Tourmaline Bio
TRML
$32.7M 0.43%
+2,538,925
New +$40.9M
THRD
46
DELISTED
Third Harmonic Bio
THRD
$26.4M 0.35%
2,033,056
– –
SLDB icon
47
Solid Biosciences
SLDB
$836M
$24.6M 0.32%
4,330,446
– –
TSHA icon
48
Taysha Gene Therapies
TSHA
$1.69B
$24.4M 0.32%
10,872,503
– –
TNYA icon
49
Tenaya Therapeutics
TNYA
$163M
$23.6M 0.31%
7,622,347
+1,867,297
+32% +$7.71M
VOR icon
50
Vor Biopharma
VOR
$1.18B
$22.7M 0.3%
1,137,444
– –
1
2
3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, RA Capital Management held 87 positions worth $7.56B, down 3.8% from $7.86B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

RA Capital Management deployed $625M of net new capital in Q2 2024, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Recursion Pharmaceuticals: 15,384,615 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was iTeos Therapeutics, an estimated $12.9M trimmed.

  • RA Capital Management's largest Q2 2024 buy was Recursion Pharmaceuticals: 15,384,615 shares worth $115M.
  • RA Capital Management added most to Climb Bio in Q2 2024, an estimated $122M increase.
  • RA Capital Management's biggest Q2 2024 reduction was iTeos Therapeutics, cutting an estimated $12.9M.
  • RA Capital Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $91.9M.
  • RA Capital Management's ten largest holdings make up 54% of its $7.56B portfolio in Q2 2024.
  • RA Capital Management opened 11 new positions and closed 9 in Q2 2024.
  • RA Capital Management's portfolio value fell 3.8% quarter-over-quarter to $7.56B.

Based on RA Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.